Labsystems Diagnostics, Shimadzu Corporation in alliance

By: |
Updated: September 08, 2016 11:57 AM

Labsystems also announced the availability of its new generation NeoMass AAAC

Labsystems also announced the availability of its new generation NeoMass AAAC

Labsystems Diagnostics, Helsinki, an enterprise of Trivitron Healthcare, headquartered in Chennai, entered into a joint association with Shimadzu Corporation, Japan, leader in analytical instruments, for clinical diagnostics in the area of Newborn Screening (NBS). NBS is a preventive paediatric screening service to assess the occurrence of genetic metabolic disorders.

Labsystems furthermore has announced the availability of its new generation NeoMass AAAC assay fully validated on Shimadzu mass spectrometry platforms. NeoMass AACC will enable investigators for the first time to detect the entire spectrum of Urea Cycle Metabolic Disorders (UCMD) in newborns.

 

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.